Wednesday, September 28, 2022
Biomind Labs Inc., a prominent biotech company dedicated to advancing the development of innovative pharmaceuticals for neurological and psychiatric disorders, is excited to announce the acquisition of a Controlled Substances License and the initiation of an eight-month project. This project aims to create and evaluate revolutionary hydrogel-forming microneedle arrays that rapidly dissolve and sustainably release medication through the skin. These arrays have been specifically designed for the transdermal delivery of Biomind's key psychedelic compounds, namely N,N-dimethyltryptamine ("DMT"), 5-methoxy-N,N-dimethyltryptamine ("5-MeO-DMT"), and mescaline.
"We are delighted to expand our operations in the United Kingdom and establish a partnership with Queen's University of Belfast, a renowned global leader in the field of rapidly-dissolving and sustained-release hydrogel-forming microneedles. This collaboration grants us a first-mover advantage in offering a groundbreaking drug delivery system that provides controlled release. Such a disruptive approach to drug delivery extends beyond the realm of psychedelic experiences and enables us to explore a wider market. We could potentially revolutionize the treatment of inflammation, pain, and neurodegenerative disorders by introducing a comfortable drug delivery solution that significantly improves therapeutic outcomes for patients. Our exclusive agreement with Queen's University of Belfast bolsters our intellectual property portfolio, which focuses on our three key psychedelic compounds: DMT, 5-MeO-DMT, and mescaline," stated Alejandro Antalich, CEO of Biomind Labs.
The utilization of polymeric microneedle array patches ("MAPs") offers an appealing avenue for transdermal drug delivery. Upon application, these microneedles painlessly penetrate the outer layer of the skin, creating temporary microchannels within the highly effective diffusion barrier. This allows for enhanced transdermal drug delivery. Given the abundance of blood vessels in the deeper layers of the skin, drugs can be absorbed into the bloodstream and distributed throughout the body, producing a systemic effect. Furthermore, this technology provides additional benefits, such as bypassing first-pass metabolism and enabling rate-controlled or long-acting drug delivery. These advantages can reduce the occurrence of side effects and dosing frequency, potentially leading to improved treatment adherence.
